IQAI stonchecker...opp! review10 Aug 2020 18:29
research ''29%¹ of the time lithotripsy fails, and the patient must undergo a surgical procedure. The cost of these failed lithotripsy procedures is therefore almost $2.3 billion per year''
Now IQAI stonechecker USA FDA approved actually reduces this mkt cost to 0! huge mkt opp - in partilcuar with a major medical opperations as they would have use costs due to the procedur, circar £100M!... 10% to Save 90% is very good business.
By teh same token, work out - 10% of mkt cost (£2.4b) values stonechecker at £230M per year. It is the only FDA approved standard, so 50% of near term mkt capture, is £115m Per year! Go figure that out first (Forget what the pps price is for now)
WHat you think DShox,the more i look into the more interesting it gets.
(I wonder who the major internal medical group is, as they will drive sales very easily - as standard de standard)
At 7m mkt cap, is has huge way to recover and re-rate, short term and long term. No brainer, and no loser here what so ever.